Issue link: http://osercommunicationsgroup.uberflip.com/i/709455
C h a i n D r u g s t o r e D a i l y 8 5 M o n d a y, A u g u s t 8 , 2 0 1 6 SC: For more than 35 years at Galderma, we've been dedicated to providing inno- vative, science-based solutions to meet the skin health needs of people through- out their lifetime. As a leader in derma- tology research and development, we're motivated by the fact that skin is our interface with the world and skin health has social and psychological implica- tions. CDD: What are the key launches this year and in early 2017? SC: We have several exciting new brands within our portfolio this year and we con- tinue to infuse innovation into our flag- ship consumer brand, Cetaphil. With a new modern look to enhance consumer shopability, a Men's line, and new Baby Eczema launches in our Baby portfolio, Cetaphil is having a very strong 2016. In January 2017, Cetaphil will launch excit- ing new innovations in Facial Skincare. Soon Differin Gel, a topical retinoid acne treatment, will be available OTC. CDD: Can you speak a bit further about the thinking behind expanding the popular Cetaphil brand into the men's category? SC: Introducing a line for men was the G alderma (C o nt'd. fro m p. 1 ) natural next step in offering skin care for the whole family. Cetaphil Men is a seven product line that cleans, moistur- izes and protects men's skin. The line was built for all skin types, including dry or sensitive, and leaves out harsh ingredi- ents and fragrances, making all products suitable for everyday use. CDD: Consumers have seen your limited edition Camp Wonder displays in the market. Can you tell our readers more about the partnership with Camp Wonder? SC: 2016 marks the 5th anniversary of Cetaphil and Galderma's partnership and support of the Children's Skin Disease Foundation and Camp Wonder, a week-long summer camp where chil- dren with chronic and sometimes life- threatening skin diseases can enjoy camp without feeling self-conscious about their skin. As a company focused on skin health and dermatology, we pro- vide grants, volunteers and Cetaphil products as part of our ongoing commit- ment to raise awareness of skin diseases. So far, we've raised more than $700,000 and are committed to doing our part to bring happiness into the lives of these inspiring children. For more information, visit booth #909. global biopharmaceutical company. Amring is uniquely positioned to leverage its partner's expertise in pep- tide-based drugs and biotechnology derived medicines, as well as patient- friendly drug delivery systems, sterile manufacturing and other state-of-the-art technologies. "At Amring, we all share a common passion for patients, customers and qual- ity. We are fortunate to have leaders that use their wealth of knowledge and expe- rience to expertly and effectively work with our customers and partners toward better patient health," says Daniel Carbery, President and General Manager of Amring Pharmaceuticals Inc. Across its organization, Amring is focused on supplying unique and special- ized products in targeted markets, with an emphasis on providing world-class customer service and high value to part- ners and patients. "We leverage every opportunity to meet specific customer demands with value-added generic medicines. Our cus- tomer service is second to none, as we are a nimble organization that is able to respond quickly to requests from both our customers and partners," explains Carbery. "In addition, we have strategi- cally positioned ourselves to make and market affordable products that add value." A mring P harmaceuticals (C ont'd. from p. 1 ) Amring is already invested in Desmopressin Acetate, a peptide-based drug that can treat diabetes insipidus, as well as certain bleeding disorders and bedwetting problems. The company's product portfolio also includes Tranexamic Acid, indicated for the treat- ment of certain bleeding disorders in women. Amring is actively seeking to add more products to its portfolio. Amring is run by a leadership team whose members bring significant experi- ence in generic pharmaceuticals and related industries. "We are senior pharmaceutical exec- utives with proven success in growing businesses from the ground up, a keen ability to quickly maximize global resources at a local level, and the com- mitment and experience to support long- term sustainable relationships. Our broad capabilities can also fill the gaps in phar- maceutical development, manufacturing, marketing and distribution," Carbery says. Backed by a notable heritage of accomplishment in the pharmaceutical industry, the Amring team looks forward to growing its market presence in the years ahead and to bringing more high- quality, dependable generic pharmaceuti- cal products to the marketplace. Visit Amring Pharmaceuticals at booth #2356. For more information, visit www.amringusa.com. Thyroid has been on the market since 1934, offering pharmacies 82 years of exemplary, consistent product. RLC's prescription medications offer high quality, natural, consistent medication at a cost effective price point, giving both pharmacy and patient a rea- son to make Nature-Throid or WP Thyroid part of their hypothyroid treat- ment. Nature-Throid and WP Thyroid are all natural T4 and T3 hormone replace- ment medications utilizing desiccated porcine extract. Most synthetic thyroid treatments contain only T4 hormone. Since both RLC products contain T4 and T3 hormones, they provide a more natu- ral body response. There is simply no substitute for the healing benefits nature provides. Nature-Throid is the classic solution for hypothyroid treatment. WP Thyroid, with fewer inactive ingredients, is now available for patients who require a more pure formula. Both medications are for- mulated using hypoallergenic inactive ingredients. There are no artificial colors or flavors, corn, peanut, rice, gluten, soy, R L C L abs (C o nt'd. fro m p. 1 ) yeast, egg or fish/shellfish. WP Thyroid and Nature-Throid contain thyroid USP. They adhere to strict United States Pharmacopeia (USP) monographs for potency and consistency and have guaranteed T4 and T3 hormone levels. Every batch is tested to ensure it meets or exceeds these USP standards. While the indus- try allows for a monograph discrepancy of +/-10 percent between T4 and T3, WP Thyroid and Nature-Throid are not released outside of +/-2 percent. WP Thyroid and Nature-Throid also com- ply with all USP pharmaceutical guide- lines and FDA manufacturing and pro- cessing. RLC's products are standardized, prescription thyroid medications. WP Thyroid uses only two all-natural inac- tive ingredients and is available in eight strengths. Nature-Throid is available in 13 strengths and is a lower-cost option. Both medications are available by pre- scription only. Both medications use the same active ingredient: Thyroid USP. Visit RLC Labs at booth #2416. For more information, go to www.getrealthyroid.com or call 602.314.7888. Mentholatum is dedicated to helping our consumers, and our topical cough and cold remedies offer an effective cough/cold solution for mothers looking for an alternative to internal medicines. We listened to their feedback, and are proud to be able to provide a much improved usage experience, through hands-free application. It's convenience that's unmatched." Research shows the Mentholatum No Mess Vaporizing Rub resonates with consumers and moms alike. During consumer testing, eight in 10 users said they would recommend the product to friends or family, with convenience being the most resounding factor. Direct quotes from consumers during testing included "I don't have to worry about covering my hands now," "less messy," "easy to apply" and "perfect for holding in hand." "The Mentholatum Company has always been dedicated to providing our Mentho latum C o mpany (C o nt'd. fro m p. 4 ) customers with the highest quality reme- dies available," said Mike Carroll, Vice President of Marketing of Mentholatum U.S. "With the launch of Mentholatum No Mess Vaporizing Rub, not only are we giving customers new options in OTC remedies, we're also continuing a long tradition of innovation to remain current with shifting customer preferences." The Mentholatum No Mess Vaporizing Rub is the latest in a full line of topical cough and cold remedies. All of Mentholatum's vaporizing rubs are formulated with 100 percent natural active ingredients. The Nighttime Vaporizing Rub's aromatic lavender scent encourages a good night's sleep while soothing coughs, while Original Ointment has been trusted for genera- tions to soothe minor aches and pains of muscles and joints and ease the discom- fort of colds. Together, these products work to meet the cough/cold treatment needs of moms nationwide. Visit Mentholatum at booth #140. PSE products, according to the Pharmacy Times and the U.S. News & World Report annual survey for 2016/2017. The effectiveness of Nexafed in reducing local meth lab incidents is sup- ported by law enforcement data. In Tennessee, pharmacies in some counties replaced older single-ingredient PSE products with Nexafed, followed by a decrease in meth labs of up to 90 percent. Since June 2014, after nearly all pharmacies in West Virginia voluntarily replaced traditional immediate release 30mg PSE products with meth-resistant products like Nexafed, law enforcement reported a 40 percent decrease in meth lab incidents in the first six months, the decline accelerating into 2015. The Charleston Gazette reports a 66 percent decrease in meth lab incidents from 2013 through June 2015. This year, Indiana legislators passed a new law to address meth production and abuse, which includes language favorable to meth-resistant products like Nexafed. Acura continues to advance its pro- prietary IMPEDE technology behind the brand with Nexafed Sinus Pressure + A cura P harmaceuticals (C o nt'd. fro m p. 4 ) Pain (PSE HCl 30 mg + acetaminophen 325 mg), a meth-resistant immediate- release tablet that relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. Nexafed Sinus Pressure + Pain, launched in February of 2015, is the first and only meth-deterring PSE combination product and also is the only pseudoephedrine/acetaminophen combi- nation product on the market. The company is also moving for- ward with IMPEDE 2.0 with the commit- ment to deliver superior meth resistance in the direct conversion, or "one pot," methamphetamine conversion process, compared with other meth-resistant tech- nologies on the market. Acura expects to launch Nexafed 12 Hour extended release pseudoephedrine in 2017. Advancing these extended-release for- mulations is crucial to Acura's strategy to develop a full-line of meth-resistant pseudoephedrine products. Extended- release products will complement the current Nexafed brand offerings and position Acura to sell into the largest seg- ment of the pseudoephedrine category. For more information, visit booth #1459.